Combination chemotherapy and monoclonal antibody

This page covers all Combination chemotherapy and monoclonal antibody drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Ribonucleotide reductase / DNA polymerase (fludarabine); CD52 (alemtuzumab), Topoisomerase I (irinotecan); EGFR (cetuximab).

Targets

Ribonucleotide reductase / DNA polymerase (fludarabine); CD52 (alemtuzumab) · Topoisomerase I (irinotecan); EGFR (cetuximab)

Phase 3 pipeline (2)

• FluCAM [Fludara + Campath] · Genzyme, a Sanofi Company · Oncology
  FluCAM combines a purine nucleoside analog that inhibits DNA synthesis with a monoclonal antibody that depletes lymphocytes, providing dual immunosuppressive and cytotoxic activity.
• Irinotecan/Cetuximab · Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente · Oncology
  Irinotecan inhibits topoisomerase I to damage cancer cell DNA, while cetuximab blocks EGFR signaling to prevent tumor growth and enhance chemotherapy sensitivity.